%D8%A5%D9%86%D8%AA%D8%B1%D9%81%D9%8A%D8%B1%D9%88%D9%86_%D8%A8%D9%8A%D8%AA%D8%A7_1-%D8%A3%D9%84%D9%81%D8%A7%D8%A7%DB%8C%D9%86%D8%AA%D8%B1%D9%81%D8%B1%D9%88%D9%86_%D8%A8%D8%AA%D8%A7-%DB%B1%D8%A7%DB%8CInterfer%C3%B3_beta_1aInterferon_beta-1aInterferon_beta-1a%D8%A7%DB%8C%D9%86%D8%AA%D8%B1%D9%81%D8%B1%D9%88%D9%86_%D8%A8%D8%AA%D8%A7-%DB%B1%D8%A7%DB%8CInterf%C3%A9ron_b%C3%AAta-1a%D7%90%D7%99%D7%A0%D7%98%D7%A8%D7%A4%D7%A8%D7%95%D7%9F_%D7%91%D7%98%D7%90_1aInterferone_beta-1aInterfer%C3%A3o_beta-1a%D0%98%D0%BD%D1%82%D0%B5%D1%80%D1%84%D0%B5%D1%80%D0%BE%D0%BD_%D0%B1%D0%B5%D1%82%D0%B0-1aInterferon_beta-1aInterferon_beta-1aInterferon_beta-1aQ2450337
about
Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon BetaSafety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta TherapySimvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple SclerosisInvestigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing AntibodiesComparison of Bone Effects With Copaxone and Interferon in Multiple SclerosisPhase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple SclerosisRNF and Betaseron® Tolerability StudyOpen Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple SclerosisStudy To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple SclerosisPost Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years PeriodPost-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®A Pilot Trial of Interferon Beta-1a in Alzheimer's DiseasePharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy SubjectsTolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple SclerosisQOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in KoreaTreatment Interruption of NatalizumabThe Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) TreatmentDemonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy VolunteersA Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)Neuroprotection With Riluzole Patients With Early Multiple SclerosisAVONEX® Combination Trial - "ACT"Rebif New Formulation (RNF) in Relapsing Forms of Multiple SclerosisInterferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver MetastasesInterferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular MelanomaDetermining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSDietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1aMATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and ColombiaNoninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple SclerosisCanadian Avonex PEN Productivity StudyA Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer SubjectsAvonex PEN Satisfaction and Patients Experience Clinical TrialColecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple SclerosisFingolimod Versus Interferon Beta 1b in Cognitive SymptomsLong-Term Safety and Efficacy Study of Peginterferon Beta-1aA Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch NeedlePortuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectorsBetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program
P4844
Q61904983-E96C1DAE-A9E6-4F19-AF86-3D340474D1B3Q61917831-16CD02E8-8D9D-4087-B5CB-DF738436109FQ61917834-1C2151FB-9523-4958-BD04-CEA5008E07E3Q61917861-A61529DE-4888-4C1A-BD94-16EADA78908EQ61917888-46920D19-A7FD-486F-B616-7312FEE32ECEQ61918013-5032D725-AF1E-4E2A-AE71-34EA4F7B28FEQ61918139-7D41A86A-60F9-456F-ABC8-C477B6F5122EQ61921265-F36744E0-A21F-4E2A-879C-A665AA00B23FQ61933413-44B6D35E-68BB-4982-932F-FAF7BF44664BQ61933882-D8A5FB82-F061-43C7-AB23-C6A630101D1BQ61935980-72116A5B-14BA-4A06-8119-4651A9746899Q61938117-F5B2D6FE-4FC6-4AEA-9AB2-1F57EAB0538DQ61938191-CF1D9F41-0B0E-4D71-802C-5BC40EB024EDQ61938201-97A0AFF2-6718-4DFA-A770-359DD884E249Q61938334-1D6B9736-DBE5-42E8-BBD4-FFC92C739413Q61938359-880F3003-E1FC-4630-93C9-8341ACE62A41Q61938660-3FE465AE-F0D9-4E85-9357-D11CB6E202CFQ61938726-BA5A2A3C-B0F9-4B87-9AF8-62DF06ED2FD0Q61939128-F2F11E1D-5D42-460B-894F-1C3977A2967AQ61957722-AF9FCC95-5239-45A6-BCC5-F472CC4E23DEQ61974970-D41F28A9-2A41-46A9-9A6A-4C08E71E422EQ61980291-13CB5E53-8080-447C-BD53-B4CA91898B87Q62105087-34064CE6-D529-4FD3-B684-F37C90EC36A4Q62105261-0B42B5A9-28D0-4AA9-A925-31D387633CBCQ62105579-D295BD49-B5FA-4892-A65D-150373B91D70Q62110697-4E7818A7-7A75-4B9B-8C38-BCFA3C936FCEQ62814572-CD9B8851-5AC7-4366-BE6D-0A36BC994826Q63317419-5A1DB6C8-EF83-4A7E-9327-CD49293FE23BQ63318104-2F701708-A03A-40E5-99F0-D1BA6B82134FQ63320622-62A80A77-68E5-4C20-9795-52945D007FC8Q63320991-9034E23E-0B3D-4D16-A227-9D841B6E6828Q63322884-5DC0213A-CB3C-460B-B8BC-994DE671ED58Q63333689-2DAF7ED1-BC3E-42F7-9ED0-8465111C61C6Q63335003-7617C581-FB2A-40A3-9CCB-9DAE0D57C34DQ63335607-F6D782CF-61B0-456E-8255-E9C329F2DEA5Q63336830-C6B2A1B8-441A-445A-9ADB-0E7157BF7F0DQ63337397-CB99A3DD-0B0C-4FEA-AD40-7A6E9081A7C2Q63338829-88864B17-EC9E-40A3-A537-B91EA36A7E85Q63340748-0C068980-E5DB-4E2C-9AFA-678F9B456627Q63340934-2EC9D906-87E8-4330-9D11-C23C4253FD3E
P4844
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Interferon beta-1a
@cs
Interferon beta-1a
@sh
Interferon beta-1a
@sr-el
Interferon beta-1a
@vi
Interferon bèta-1a
@nl
Interferone beta-1a
@it
interferon beta-1a
@en
interferon beta-1a
@nn
interferão beta-1a
@pt
interferó beta 1a
@ca
type
label
Interferon beta-1a
@cs
Interferon beta-1a
@sh
Interferon beta-1a
@sr-el
Interferon beta-1a
@vi
Interferon bèta-1a
@nl
Interferone beta-1a
@it
interferon beta-1a
@en
interferon beta-1a
@nn
interferão beta-1a
@pt
interferó beta 1a
@ca
altLabel
145258-61-3
@fr
Avonex
@cs
Avonex
@nl
Avonex
@ru
Avonex
@sr
C908H1406N246O252S7
@fr
CinnoVex
@cs
CinnoVex
@sr
Fibroblast interferon
@en
IFN beta 1a
@en
prefLabel
Interferon beta-1a
@cs
Interferon beta-1a
@sh
Interferon beta-1a
@sr-el
Interferon beta-1a
@vi
Interferon bèta-1a
@nl
Interferone beta-1a
@it
interferon beta-1a
@en
interferon beta-1a
@nn
interferão beta-1a
@pt
interferó beta 1a
@ca
P2175
P2868
P31
P486
P592
P6366
P646
P2115
N0000022030
P2175
P2275
Interferon beta-1a
@en
P231
145258-61-3
P267
P3345
P486
D000068556
P592
CHEMBL1201562
P6366
2909783426
2910626342
P646
P652
XRO4566Q4R